The Treatment of HCV in Patients with Haemoglobinopathy in Kurdistan Region, Iraq: a Single Centre Experience

Overview

Journal Epidemiol Infect

Publisher Cambridge University Press

Specialties Infectious Diseases
Public Health

Date 2016 Apr 30

PMID 27125573

Citations 4

Authors

N R Hussein

I Tunjel

Z Basharat

A Taha

W Irving

Affiliations

Soon will be listed here.

Abstract

Various variables that might influence the rapid and sustained virological response to recombinant PEG-IFN-α-2a were explored in Iraqi HCV-infected patients with haemoglobinopathy. Forty-three patients were evaluated for the relationship between rapid virological response (RVR), IL-28B polymorphism, viral load, liver enzyme levels, blood group, ultrasound findings, or HCV genotype and the sustained virological response (SVR) achievement. The overall RVR was 55·81% while the overall SVR was 53·49%. SVR in patients that achieved RVR was 82·61% (P = 0·0004). A significant association was found between initial alanine transaminase levels and viral load with SVR achievement (P = 0·025) and (P = 0·004), respectively. Thirty-two (74%) out of 43 of our samples were host genotyped at the IL-28B locus as CC, a significant association was found between CC group and SVR achievement (P = 0·04). Of our samples, 23/43 (53%) were typed as HCV genotype 4, 10/43 (23%) as genotype 1, 9/43 (20·9%) as genotype 3 and 1/43 (2·3%) as genotype 2. A significant association was found between genotype 3 and SVR achievement (P = 0·006). Multivariate analysis showed that only RVR achievement independently associated with SVR in the Iraqi population (P = 0·00). These results can be used to classify the patients requiring the more expensive new direct-acting antiviral drugs.

Citing Articles

Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection.

Hussein N, Saleema Z, Abd Q Mediterr J Hematol Infect Dis. 2019; 11(1):e2019034.

PMID: 31205638 PMC: 6548205. DOI: 10.4084/MJHID.2019.034.

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection.

Alkaaby B, Al-Ethawi A Pak J Med Sci. 2018; 34(6):1353-1356.

PMID: 30559784 PMC: 6290209. DOI: 10.12669/pjms.346.15722.

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy.

Hussein N Mediterr J Hematol Infect Dis. 2017; 9(1):e2017005.

PMID: 28105296 PMC: 5224801. DOI: 10.4084/MJHID.2017.005.

Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?.

Zachou K, Arvaniti P, Gatselis N, Azariadis K, Papadamou G, Rigopoulou E Mediterr J Hematol Infect Dis. 2017; 9(1):e2017003.

PMID: 28101309 PMC: 5224816. DOI: 10.4084/MJHID.2017.003.

References

Parruti G, Polilli E, Sozio F, Cento V, Pieri A, Di Masi F . Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin. Antiviral Res. 2010; 88(1):124-7. DOI: 10.1016/j.antiviral.2010.08.003. View

Poordad F, Reddy K, Martin P . Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. 2008; 46(1):78-84. DOI: 10.1086/523585. View

Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. DOI: 10.1038/nature08309. View

Kamal S, El Tawil A, Nakano T, He Q, Rasenack J, Hakam S . Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005; 54(6):858-66. PMC: 1774522. DOI: 10.1136/gut.2004.057182. View

Koshy A, Madda J, Marcellin P, Martinot M . Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol. 2002; 35(1):82-5. DOI: 10.1097/00004836-200207000-00017. View

Ohno T, Mizokami M, Saleh M, Orito E, Ohba K, Wu R . Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients. Arch Virol. 1996; 141(6):1101-13. DOI: 10.1007/BF01718613. View

Messina J, Humphreys I, Flaxman A, Brown A, Cooke G, Pybus O . Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2014; 61(1):77-87. PMC: 4303918. DOI: 10.1002/hep.27259. View

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. DOI: 10.1038/ng.449. View

Al-Kubaisy W, Al-Naib K, Habib M . Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. East Mediterr Health J. 2006; 12(1-2):204-10. View

10.

Ferreira C, Abreu R, da Silva M, Siqueira Ferreira A, Nasser P, Carrilho F . A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. PLoS One. 2013; 8(10):e78142. PMC: 3805516. DOI: 10.1371/journal.pone.0078142. View

11.

Martin-Carbonero L, Nunez M, Marino A, Alcocer F, Bonet L, Garcia-Samaniego J . Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 2007; 22(1):15-21. DOI: 10.1097/QAD.0b013e3282f1da99. View

12.

Lin R, Liao C, Lin E, Lin Y . Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J Virol. 2004; 78(17):9285-94. PMC: 506928. DOI: 10.1128/JVI.78.17.9285-9294.2004. View

13.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View

14.

Rivero-Juarez A, Lopez-Cortes L, Camacho A, Torres-Cornejo A, Gordon A, Ruiz-Valderas R . HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients. PLoS One. 2014; 9(6):e99468. PMC: 4063713. DOI: 10.1371/journal.pone.0099468. View

15.

Samuel C . Antiviral actions of interferons. Clin Microbiol Rev. 2001; 14(4):778-809, table of contents. PMC: 89003. DOI: 10.1128/CMR.14.4.778-809.2001. View

16.

Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P . Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010; 116(16):2875-83. DOI: 10.1182/blood-2009-11-248724. View

17.

Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L . Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol. 2004; 74(2):246-52. DOI: 10.1002/jmv.20170. View

18.

Huang C, Huang J, Yang J, Hsieh M, Lin Z, Chen S . Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol. 2011; 56(1):34-40. DOI: 10.1016/j.jhep.2011.03.029. View

19.

Tabatabaei S, Alavian S, Keshvari M, Behnava B, Miri S, Karimi Elizee P . Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012; 12(6):372-81. PMC: 3412553. DOI: 10.5812/hepatmon.6592. View

20.

Hoofnagle J, Seeff L . Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006; 355(23):2444-51. DOI: 10.1056/NEJMct061675. View